|

The Effect of Semaglutide on Cardiovascular Markers and Liver Function

NOT_RECRUITINGSponsored by Attikon Hospital
No longer actively recruiting
SponsorAttikon Hospital
Started2022-03-01
Est. completion2023-03-01
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06301191

Summary

Fifty patients with diabetes mellitus type 2 and non-alcoholic fatty liver disease (NAFLD) will be enrolled in the study. 25 patients will treated with semaglutide and 25 patients with dipeptidyl peptidase 4 (D-PP4) inhibitors. At baseline, at four and at 12 months will evaluate the endothelial, cardiovascular and liver function.

Eligibility

Age: 18 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

* Diabetes Mellitus type 2
* NAFLD

Exclusion Criteria:

* malignancies
* chronic inflammatory disease
* chronic kidney disease (estimated glomerular filtration rate \<60 ml/min/m2 for a period of at least 90 days)
* peripheral vascular disease
* retinopathy
* previous therapy with a Glucagon-like peptide-1 agonist.
* None of the female patients was on hormone replacement treatment.

Conditions3

DiabetesDiabetes Type 2Liver Disease

Interventions2

Dipeptidyl Peptidase 4 inhibitorSemaglutide, 1.0 mg/mL

Related trials

Browse More Trials

Diabetes trialsLiver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.